Literature DB >> 28833219

Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review.

J Cid1.   

Abstract

BACKGROUND AND OBJECTIVES: Transfusion-associated graft-versus-host disease (TA-GVHD) is a serious complication of blood component transfusion therapy, caused by donor T lymphocytes. γ-Irradiation or pathogen inactivation methods, capable of inactivating proliferating T cells in blood components, should be selected to prevent TA-GVHD. This review summarizes the published evidence to support the use of pathogen-reduced platelets with amotosalen (150 μm) and ultraviolet A light (UVA, 320-400 nm, 3 J/cm2 ) for preventing TA-GVHD.
MATERIALS AND METHODS: Available literature on the use of pathogen-reduced platelets to prevent TA-GVHD was reviewed.
RESULTS: Observational studies, animal models, in vitro studies and mechanistic studies of pathogen-reduced platelets with amotosalen and UVA light showed that inactivation of T cells are equal or even superior to γ-irradiation.
CONCLUSION: Pathogen-reduced platelets with amotosalen and UVA light can be used as a measure to prevent TA-GVHD.
© 2017 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion.

Entities:  

Keywords:  TA-GVHD; pathogen-reduced platelets; platelet transfusion

Mesh:

Substances:

Year:  2017        PMID: 28833219     DOI: 10.1111/vox.12558

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  7 in total

Review 1.  Treatment of inherited thrombocytopenias.

Authors:  Carlo L Balduini
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

2.  Recommendations on Selection and Processing of RBC Components for Pediatric Patients From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.

Authors:  Nicole D Zantek; Robert I Parker; Leo M van de Watering; Cassandra D Josephson; Scot T Bateman; Stacey L Valentine; Meghan Delaney
Journal:  Pediatr Crit Care Med       Date:  2018-09       Impact factor: 3.624

3.  Preventing transfusion-associated graft-versus-host disease with blood component irradiation: indispensable guidance for a deadly disorder.

Authors:  Sorcha Ní Loingsigh; Willy A Flegel; Jeanne E Hendrickson; Christopher A Tormey
Journal:  Br J Haematol       Date:  2020-08-01       Impact factor: 8.615

4.  How do you… decide which platelet bacterial risk mitigation strategy to select for your hospital-based transfusion service?

Authors:  Wen Lu; Meghan Delaney; Willy A Flegel; Paul Ness; Nora Ratcliffe; Darrell J Triulzi; Mark H Yazer; Alyssa Ziman; Nancy M Dunbar
Journal:  Transfusion       Date:  2020-02-06       Impact factor: 3.337

5.  Pathogen reduction of double-dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects.

Authors:  Konrad Rosskopf; Wolfgang Helmberg; Peter Schlenke
Journal:  Transfusion       Date:  2020-07-03       Impact factor: 3.157

6.  Protein Concentrations in Stored Pooled Platelet Concentrates Treated with Pathogen Inactivation by Amotosalen Plus Ultraviolet a Illumination.

Authors:  Niels Arni Arnason; Freyr Johannsson; Ragna Landrö; Björn Hardarsson; Sveinn Gudmundsson; Aina-Mari Lian; Janne Reseland; Ottar Rolfsson; Olafur E Sigurjonsson
Journal:  Pathogens       Date:  2022-03-14

7.  In Vitro Comparative Study of Platelets Treated with Two Pathogen-Inactivation Methods to Extend Shelf Life to 7 Days.

Authors:  Nicolas Malvaux; Fanette Defraigne; Styliani Bartziali; Camille Bellora; Kathleen Mommaerts; Fay Betsou; Anne Schuhmacher
Journal:  Pathogens       Date:  2022-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.